耐受性单核细胞来源朗格汉斯细胞通过AhR-COX-2促进黑色素瘤进展及免疫治疗耐药
研究探讨了黑色素瘤中朗格汉斯细胞(LC)亚群的功能异质性,发现随疾病进展肿瘤组织内驻留LC减少而单核细胞来源LC(moLC)增多,且moLC频率在抗PD-1治疗耐药患者中更高。小鼠模型显示清除驻留LC加速肿瘤生长,而清除moLC则抑制肿瘤进展;机制上TGF-β激活moLC的芳香烃受体-环氧合酶-2信号,促进前列腺素E2产生和PD-L1表达,抑制CD8+细胞毒性T淋巴细胞。
要点
- 黑色素瘤进展伴随驻留LC减少和moLC增多,moLC频率与抗PD-1耐药相关。
- 清除驻留LC加速肿瘤生长,清除moLC抑制肿瘤进展,提示亚群功能相反。
- moLC通过TGF-β-AhR-COX-2轴产生PGE2并表达PD-L1,抑制CD8+ T细胞。
核心结论
- moLC通过TGF-β激活AhR-COX-2信号产生PGE2和表达PD-L1,发挥免疫抑制并促进黑色素瘤进展及免疫治疗耐药。
研究设计与样本
- 研究纳入黑色素瘤患者肿瘤组织观察LC亚群变化,并使用muLangerin-DTR转基因和moLC特异性敲除小鼠模型进行功能验证。
主要发现
- 随疾病进展,黑色素瘤肿瘤组织内驻留LC减少而moLC增多。
- moLC频率在抗PD-1治疗耐药患者中高于治疗响应者。
- 清除驻留LC加速黑色素瘤生长,清除moLC抑制肿瘤进展。
- moLC较驻留LC环氧合酶-2相关基因表达升高。
- TGF-β激活moLC的AhR-COX-2信号,增加PGE2产生和PD-L1表达,抑制CD8+细胞毒性T淋巴细胞。
关键数值与推荐
- moLC频率在抗PD-1治疗耐药黑色素瘤患者中高于响应者。
- moLC较驻留LC环氧合酶-2相关基因表达升高。
- TGF-β激活moLC的AhR-COX-2信号,导致PGE2产生增加和PD-L1表达。
临床怎么用
- moLC频率或可辅助识别抗PD-1治疗耐药风险较高的黑色素瘤患者。
- 靶向moLC的TGF-β-AhR-COX-2轴可能成为克服免疫治疗耐药的潜在策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Langerhans cells (LCs), as epidermal-resident antigen-presenting cells, are among the first to encounter early carcinogenic changes in the skin, such as those seen in melanoma. During inflammation or cancer, circulating monocytes are recruited into the epidermis, replacing resident LCs that have migrated to draining lymph nodes. However, the specific roles of LC subsets in the progression of melanoma remain unclear. In this study, we observed a decrease in resident LCs and an increase in monocyte-derived LCs (moLCs) within melanoma tumor tissues as the disease progressed. Notably, the frequency of moLCs was higher in patients with anti-PD-1 therapy-resistant melanoma than in those responsive to the therapy. Using muLangerin-DTR transgenic and moLC-specific knockout mouse models, we demonstrated that the depletion of resident LCs accelerated melanoma growth, whereas the depletion of moLCs suppressed tumor progression. Mechanistically, moLCs exhibited elevated expression of cyclooxygenase-2-related genes compared with resident LCs. TGF-β was found to activate aryl hydrocarbon receptor-cyclooxygenase-2 signaling in moLCs, leading to increased production of prostaglandin E2 and expression of PD-L1, which collectively contributed to the immunosuppressive effects of moLCs on CD8+ cytotoxic T lymphocytes. In summary, our findings highlight the functional heterogeneity of LC subsets in melanoma progression, offering deeper insights into LC biology and potential therapeutic strategies.
引用
- Dong L, Wu N, Cai Z, et al. Tolerogenic Monocyte-Derived Langerhans Cells Promote Melanoma Progression and Immunotherapy Resistance through Aryl Hydrocarbon Receptor-Cyclooxygenase-2 Activation. J Invest Dermatol. 2025. PMID: 40216154. doi:10.1016/j.jid.2025.02.155
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。